Johnson & Johnson (JNJ) said it doesn’t intend to make an offer for Horizon Therapeutics (HZNP), days after the developer of medicines for rare autoimmune and inflammatory diseases revealed it was in talks with the company, Bloomberg’s Susanne Barton reports. Janssen Global Services, J&J’s pharmaceutical division, didn’t provide a reason why it isn’t planning on proceeding with an offer, the author notes. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Needham healthcare analyst to hold an analyst/industry conference call
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
- Cidara Therapeutics announces issuance of first U.S. patent for CD388
- Johnson & Johnson names CEO Joaquin Duato as Chairman of the Board